LL-37 and mold illness: what the peptide science actually shows

What's this video probably claiming?

Based on the caption, hashtags, and the fact that this is part five of an ongoing mold illness and peptide series, @daniellenutritionist is almost certainly positioning LL-37 as a therapeutic tool for people suffering from chronic inflammatory response syndrome (CIRS) or what the wellness community broadly calls "mold illness." The likely framing: LL-37 is a naturally occurring antimicrobial peptide your body produces, mold exposure depletes or disrupts your innate immune response, and supplementing or injecting exogenous LL-37 can restore that defense. The antifungal hashtag strongly suggests the video leans on LL-37's documented antifungal properties in lab settings. There's probably a claim that people with mold illness have low LL-37 levels, and that peptide therapy can help fill that gap. This is a recurring narrative in functional and integrative medicine circles, and it maps closely to how this creator has framed prior episodes in the series.

What does the science actually show?

LL-37 is a real peptide. It's the only member of the cathelicidin family found in humans, produced mainly by neutrophils, epithelial cells, and macrophages. It does have documented antimicrobial and antifungal activity in vitro. A 2018 study by Luca et al. in Frontiers in Microbiology confirmed LL-37 disrupts fungal cell membranes, including Candida species, at micromolar concentrations in cell cultures. The problem is that "works in a petri dish" is doing a lot of heavy lifting here. There are no published randomized controlled trials of exogenous LL-37 injected in humans for any indication as of 2024. Most human research involves LL-37 as a biomarker measured in tissue samples or wound fluids, not as an administered therapeutic. A 2020 review by Mansour et al. in Chemical Reviews noted that cathelicidin-derived peptides face significant stability and delivery challenges in vivo, including rapid protease degradation. The leap from "this peptide exists in your immune system" to "injecting it will fix mold illness" is not supported by current clinical evidence.

Where does the social media noise diverge from clinical reality?

The core divergence is between mechanistic plausibility and clinical proof. LL-37 enthusiasts in the peptide community frequently cite its immune-modulating properties, noting that Shoemaker-protocol CIRS patients sometimes show abnormal innate immune markers. That part is partially grounded in real observation. But the claim that exogenous LL-37 administration corrects those deficits in a meaningful, safe, and durable way in living humans is unsupported. "Mold illness" itself sits in contested diagnostic territory. A 2017 systematic review by Tuuminen and Rinne in Frontiers in Immunology found that while mycotoxin exposure is a legitimate concern, CIRS as a defined diagnostic entity lacks standardized criteria accepted by major immunology or pulmonology bodies. Layering an experimental peptide onto a contested diagnosis and calling it a recovery protocol is a significant clinical stretch. The antifungal framing is particularly misleading because the concentrations required to achieve antifungal effects in vitro are far from what any current delivery method reliably achieves in human tissue.

What should you actually know?

If you're dealing with symptoms attributed to mold exposure, the evidence-based starting points are environmental remediation, standardized allergy testing, and evaluation by a board-certified allergist or pulmonologist, not a peptide protocol. LL-37 as a compounded injectable is not FDA-approved for any indication. The FDA has specifically flagged several peptides as ineligible for compounding under 503A and 503B regulations, and the regulatory status of LL-37 specifically warrants caution before anyone considers sourcing it. Anyone telling you that a peptide series on TikTok constitutes a treatment plan for a complex immune condition is selling you certainty that the science has not earned. If a provider is recommending exogenous LL-37 for mold illness, ask them for the clinical trial data. There isn't any. That's not gatekeeping, that's just reading the literature.